Gastrointestinal Stromal Tumor Clinical Trials

44 recruitingLast updated: June 18, 2026

There are 44 actively recruiting gastrointestinal stromal tumor clinical trials across 33 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3. Top locations include Boston, Massachusetts, United States, Beijing, Beijing Municipality, China, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Gastrointestinal Stromal Tumor Trials at a Glance

44 actively recruiting trials for gastrointestinal stromal tumor are listed on ClinicalTrialsFinder across 6 cities in 33 countries. The largest study group is Phase 2 with 17 trials, with the heaviest enrollment activity in Boston, Beijing, and Houston. Lead sponsors running gastrointestinal stromal tumor studies include Asan Medical Center, Peking University People's Hospital, and Xinhua Zhang, MD.

Browse gastrointestinal stromal tumor trials by phase

Treatments under study

About Gastrointestinal Stromal Tumor Clinical Trials

Looking for clinical trials for Gastrointestinal Stromal Tumor? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Gastrointestinal Stromal Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Gastrointestinal Stromal Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 44 trials

Recruiting

Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis

Gastric CancerGastric NeoplasmGastrointestinal Stromal Tumor (GIST)+2 more
National Cancer Institute (NCI)400 enrolled1 locationNCT04557969
Recruiting
Phase 3

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Metastatic CancerAdvanced Gastrointestinal Stromal Tumors
Cogent Biosciences, Inc.482 enrolled126 locationsNCT05208047
Recruiting
Phase 2Phase 3

Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

GIST - Gastrointestinal Stromal TumorAdvanced
Ningbo Newbay Technology Development Co., Ltd255 enrolled32 locationsNCT07379047
Recruiting
Phase 2

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Pancreatic Neuroendocrine TumorVon Hippel-Lindau DiseasePheochromocytoma/Paraganglioma+2 more
Merck Sharp & Dohme LLC355 enrolled84 locationsNCT04924075
Recruiting
Phase 1

Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumors
University of California, San Diego18 enrolled1 locationNCT07171203
Recruiting
Phase 2

PH 2 Pemigatinib in SDH-deficient GIST

SDH Gene MutationGastrointestinal Stromal Tumor
Dana-Farber Cancer Institute24 enrolled1 locationNCT07434843
Recruiting
Not Applicable

A Novel Two-Tooth Clip for ESD and EFTR of GIST

GIST - Gastrointestinal Stromal Tumor
Affiliated Hospital to Academy of Military Medical Sciences60 enrolled1 locationNCT07581977
Recruiting
Phase 2

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting

GISTGIST - Gastrointestinal Stromal TumorGastrointestinal Tumors+2 more
Kumquat Biosciences Inc.46 enrolled8 locationsNCT07406633
Recruiting
Phase 1Phase 2

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckOvarian Neoplasms+8 more
Cancer Research UK167 enrolled4 locationsNCT06380816
Recruiting

Integrated Cancer Repository for Cancer Research

Breast CancerLiver CancerEsophageal Cancer+47 more
University of Nebraska999,999 enrolled42 locationsNCT02012699
Recruiting
Phase 1

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

Metastatic CancerGastrointestinal NeoplasmsGastrointestinal Diseases+2 more
IDRX, Inc., a wholly owned subsidiary of GSK, LLC278 enrolled31 locationsNCT05489237
Recruiting
Phase 2

Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment

GIST - Gastrointestinal Stromal TumorKIT Gene Mutation
Jian Li100 enrolled1 locationNCT07559864
Recruiting
Phase 2

A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments

Unresectable Gastrointestinal Stromal Tumor (GIST)Locally Advanced Gastrointestinal Stromal Tumor (GIST)Metastatic Gastrointestinal Stromal Tumor
Centre Leon Berard110 enrolled13 locationsNCT05152472
Recruiting
Not Applicable

MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT

Gastrointestinal Stromal Tumor of StomachSubmucosal Tumor of Stomach
Peking University People's Hospital96 enrolled1 locationNCT06748690
Recruiting
Phase 1

A Study of HQP1351 in Patients With GIST or Other Solid Tumors

Solid Tumor, AdultGastrointestinal Stromal Tumor (GIST)
Ascentage Pharma Group Inc.100 enrolled6 locationsNCT03594422
Recruiting
Phase 2

GIST Oral Paclitaxel(Liporaxel)

Gastrointestinal Stromal Tumors
Asan Medical Center28 enrolled1 locationNCT06326346
Recruiting
Phase 2

Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumors
Asan Medical Center48 enrolled1 locationNCT05905887
Recruiting
Phase 2

The Efficacy and Safety of Temozolomide in SDH-deficient GIST

Gastrointestinal Stromal Tumors
Asan Medical Center29 enrolled1 locationNCT05661643
Recruiting
Phase 2

Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring

Carcinoma, Small CellNeuroendocrine TumorsGastrointestinal Stromal Tumors+11 more
Centre Oscar Lambret88 enrolled3 locationsNCT05500391
Recruiting
Phase 2

Imatinib TDM in GIST

Gastrointestinal Stromal Tumors
Reema A. Patel28 enrolled1 locationNCT05493215